Liaoning Weibang Biological Pharmaceutical

Liaoning Weibang Biological Pharmaceutical is a China-based pharmaceutical company focused on finished-dose medicines and biologic-enzyme products. Publicly available information indicates the company manufactures multiple dosage forms, including tablets, ointments, lyophilized injectables, and large-volume injections, and has historically marketed more than 60 products. The company appears to be particularly associated with collagenase-based wound care and debridement products, and at least one collagenase ointment program has entered Phase 2 clinical testing for diabetic foot ulcers. Patent and market sources also link the company to flurbiprofen axetil formulations and related process development. Overall, WeiBang Biopharm looks like a small Chinese specialty pharma manufacturer with activity in wound care, hospital-use formulations, and enzyme-based therapeutics.